Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Bone Marrow Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm
Bone Marrow Neoplasm

Cancer Family

Bone Marrow Neoplasm

CI-CAN-00000093Explore in graph →

Non-malignant1,034 active trials28 approved drugs633 evidence items

NCIt: C35370
MeSH: D019046

Overview
Statistics
Survival
Genomics18
Variants & evidence633
Drugs53
Trials4612
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (219)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 219 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
· Leukemia · 2014 · PMID 25212276 · validated civic_curation pubmed
Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions.
· Eur J Hum Genet · 2008 · PMID 18478040 · validated civic_curation pubmed
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
· Cancer Res · 2005 · PMID 15930265 · validated civic_curation pubmed
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
· Leukemia · 2004 · PMID 14737077 · validated civic_curation pubmed
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
· Mol Cancer Ther · 2011 · PMID 21482694 · validated civic_curation pubmed
The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.
· Biochem Biophys Res Commun · 2004 · PMID 15194504 · validated civic_curation pubmed
Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
· Leukemia · 2002 · PMID 12357354 · validated

Showing 176–200 of 219 publications

← Previous
1
…
7
8
9
Next →

civic_curation

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

· Cancer Res · 2016 · PMID 27671675 · validated civic_curation pubmed

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

· J Clin Oncol · 2009 · PMID 19075254 · validated civic_curation pubmed

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.

· Mol Cancer · 2013 · PMID 23497317 · validated civic_curation pubmed

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

· Cancer Discov · 2017 · PMID 28193778 · validated civic_curation pubmed

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

· Blood · 2013 · PMID 24081659 · validated civic_curation pubmed

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.

· Invest New Drugs · 2017 · PMID 28516360 · validated civic_curation pubmed

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.

· Leukemia · 2013 · PMID 22858906 · validated civic_curation pubmed

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.

· Blood · 2006 · PMID 16434489 · validated civic_curation pubmed

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.

· Oncotarget · 2017 · PMID 28077790 · validated civic_curation pubmed

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

· ACS Med Chem Lett · 2018 · PMID 29670690 · validated civic_curation pubmed

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

· Cancer Cell · 2008 · PMID 18394554 · validated civic_curation pubmed

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

· Blood · 2005 · PMID 15626738 · validated civic_curation pubmed

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

· Blood · 2011 · PMID 21719597 · validated civic_curation pubmed

Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.

· PLoS One · 2013 · PMID 24236021 · validated civic_curation pubmed

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.

· Nat Chem Biol · 2015 · PMID 26436839 · validated civic_curation pubmed

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

· Blood · 2013 · PMID 23430109 · validated civic_curation pubmed

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

· Cancer Res · 2009 · PMID 19318574 · validated civic_curation pubmed

Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

· Nat Chem Biol · 2015 · PMID 26167872 · validated civic_curation pubmed